ENDRA Life Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated July 25, 2023, reports on corporate governance events for ENDRA Life Sciences Inc. (NDRA). The filing addresses the reconvening and subsequent adjournment of the Company's 2023 Annual Meeting of Stockholders due to a lack of quorum.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on procedural matters regarding the Annual Meeting and contains no financial performance data.
Material Changes
The primary material event is the procedural adjournment of the Annual Meeting:
- The meeting was reconvened on July 25, 2023, following a previous adjournment on July 6, 2023, due to insufficient quorum.
- The meeting was adjourned again to August 9, 2023, at 10:00 am Eastern Time.
- No changes have been made to the proposals to be voted on by stockholders.
Outlook, Risks, and Management Commentary
Management is continuing to solicit votes from stockholders during the adjournment period. The reconvened meeting will be held virtually. Stockholders who have already voted do not need to recast their votes, and previously submitted proxies remain valid unless revoked. The Company urges security holders to read the definitive proxy statement filed on May 24, 2023, before making voting decisions.
Key Facts for Investor Verification
- New Meeting Date: August 9, 2023, at 10:00 am Eastern Time.
- Voting Deadline: Votes should be submitted by Tuesday, August 8, 2023, at 11:59 pm Eastern Time, though votes received before the close of the meeting on August 9 will be accepted.
- Meeting Format: Virtual meeting accessible via www.virtualshareholdermeeting.com/NDRA2023.
- Quorum Status: The meeting was adjourned twice due to a lack of quorum; the Company is actively soliciting additional votes.
- Document Reference: Definitive proxy statement available at the SEC website (File No. 001-37969).